# Evidence Update: Omega-3 Fatty Acids
## Date: 2026-03-04
## Previous Tier: 1 → Current Tier: 1 (Confirmed)
## Quality Score: 92 → 94 (+2)

---

## Summary

Mode 2 evidence update for Omega-3 Fatty Acids (ID 4). Searched PubMed and Consensus for new research published after August 2025. Found ~40 unique candidate papers from 631 raw results across 3 search strategies. Screened to 6 high-quality inclusions (5 meta-analyses, 1 systematic review). Evidence significantly expands Omega-3's benefit domains while adding an important negative finding (PAD) and pregnancy safety data.

---

## New Papers Added (6)

### 1. Chen et al. 2025 — AMD Prevention Meta-Analysis
- **PMID:** 41482231
- **DOI:** 10.1016/j.tjnut.2025.101289
- **Type:** Systematic review and meta-analysis (18 observational studies)
- **Key Finding:** Higher omega-3 intake associated with 20% lower AMD risk (OR = 0.80). DHA showed stronger association than EPA. Strongest protection for advanced AMD and nAMD.
- **Assigned to:** Benefits → "Eye Health" (updated existing entry)

### 2. Basirat & Merino-Torres 2025 — Metabolic Syndrome Meta-Analysis
- **PMID:** 41156531
- **DOI:** 10.3390/nu17203279
- **Type:** Meta-analysis of 21 RCTs (~1,950 participants)
- **Key Finding:** High-dose omega-3 (>2000mg/day) produced TG reductions up to -56.78 mg/dL. Clear dose-response relationship. LDL may increase at low doses.
- **Assigned to:** Benefits → "Metabolic Syndrome" (NEW domain)

### 3. Dao et al. 2025 — Peripheral Arterial Disease Meta-Analysis (NEGATIVE)
- **PMID:** 40940198
- **DOI:** 10.1016/j.numecd.2025.104286
- **Type:** Systematic review and meta-analysis (12 studies, n=759)
- **Key Finding:** Mixed omega-3 in low doses NOT effective for PAD symptoms. Important negative finding that prevents overgeneralization of cardiovascular benefits.
- **Assigned to:** Benefits → "Cardiovascular Health" (additional nuancing evidence)

### 4. Zhou et al. 2025 — MASLD/Liver Meta-Analysis
- **PMID:** 39927279
- **DOI:** 10.3389/fnut.2025.1524830
- **Type:** Meta-analysis of 7 RCTs (n=439)
- **Key Finding:** Fish oil significantly improved TG (SMD -0.40), AST (SMD -0.29), HOMA-IR (SMD -2.06), and waist circumference (SMD -0.31) in MASLD patients.
- **Assigned to:** Benefits → "Liver Health (MASLD)" (NEW domain)

### 5. Khalafi et al. 2025 — Exercise + Omega-3 Meta-Analysis
- **Source:** Consensus API
- **Type:** Meta-analysis of 21 studies (n=673)
- **Key Finding:** Adding omega-3 to exercise training reduced fat mass (-1.05kg), SBP (-4.09mmHg), DBP (-4.26mmHg), and TNF-α, while enhancing lower-body muscular strength (SMD 0.42) vs exercise alone.
- **Assigned to:** Benefits → "Exercise Synergy" (NEW domain)

### 6. Rajati et al. 2025 — Preeclampsia Prevention Meta-Analysis
- **PMID:** 39423927
- **DOI:** 10.1016/j.clnesp.2024.10.146
- **Type:** Meta-analysis of 16 studies (n=16,237)
- **Key Finding:** Omega-3 reduced total preeclampsia risk by 37% (RR 0.63, 95% CI: 0.41-0.95) and severe preeclampsia by 55% (RR 0.45, 95% CI: 0.24-0.83). Very large sample size.
- **Assigned to:** Safety → "Pregnancy Safety and Benefits" (NEW entry)

---

## Evidence Changes

### Strengthened Areas
1. **Eye health (AMD)** — Updated from a single RCT (AREDS2 with mixed results) to now include a meta-analysis of 18 studies showing 20% risk reduction with high omega-3 dietary intake.
2. **Cardiovascular health** — Now includes a balanced negative finding (PAD) alongside strong positive data, providing more complete evidence picture.

### New Domains Added
3. **Metabolic syndrome** — High-dose omega-3 (>2000mg/day) established as effective for TG reduction with clear dose-response relationship (21 RCTs).
4. **Liver health (MASLD)** — Fish oil improves multiple MASLD markers including insulin resistance (HOMA-IR SMD -2.06).
5. **Exercise synergy** — Omega-3 augments exercise training effects on body composition and cardiometabolic markers.
6. **Pregnancy safety/benefits** — Large meta-analysis (n=16,237) showing significant preeclampsia risk reduction.

### Important Negative Finding
7. **Peripheral arterial disease** — Omega-3 NOT effective for PAD symptoms in low-to-moderate doses. This adds important nuance and prevents overgeneralization.

### Unchanged Areas
- Core mechanisms: Membrane fluidity, neuroinflammation, BDNF, neuroprotection
- Depression evidence: Still strong (Liao 2019 meta-analysis)
- Cognitive evidence: Still moderate (Zhang 2024 meta-analysis)
- Dosage guidance: 1000-2000mg daily EPA+DHA confirmed
- Safety profile: Excellent rating maintained, bleeding risk still low

---

## Quality Score Breakdown

| Component | Previous | Current | Change |
|-----------|----------|---------|--------|
| Number and quality of RCTs | 28/30 | 29/30 | +1 (metabolic syndrome adds 21 RCTs) |
| Presence of meta-analyses | 18/20 | 20/20 | +2 (AMD + metabolic syndrome MAs) |
| Sample sizes | 13/15 | 13/15 | 0 |
| Replication across groups | 13/15 | 13/15 | 0 |
| Consistency of findings | 9/10 | 9/10 | 0 (PAD negative finding slightly offsets) |
| Recency of evidence | 10/10 | 10/10 | 0 |
| **TOTAL** | **92/100** | **94/100** | **+2** |

---

## Recommendation Impact

- **Tier unchanged:** Tier 1 (Gold Standard) — strongly confirmed
- **Effect sizes updated:** Added quantitative preeclampsia RR, metabolic syndrome TG reduction, and exercise synergy effects
- **New benefit domains:** Metabolic syndrome, liver health, exercise synergy added
- **Safety update:** Pregnancy benefits established with very large sample size
- **Important caveat added:** PAD negative finding documented
- **No changes to core dosage guidance or safety rating**

---

## Files Modified

| File | Action |
|------|--------|
| `data/enhanced_citations/4_enhanced.js` | Added 6 new citations, updated evidenceProfile |
| `data/supplements.js` | Updated ID 4 inline entry (totalCitations, qualityScore, lastEvidenceUpdate, effectSizes, keyCitations, primaryBenefits) |
| `content/provenance/omega_3_fatty_acids/search_log.md` | Created |
| `content/provenance/omega_3_fatty_acids/screening_decisions.md` | Created |
| `content/provenance/omega_3_fatty_acids/evidence_evaluation.md` | Created |
| `content/provenance/omega_3_fatty_acids/tier_assignment.md` | Created |
| `content/provenance/omega_3_fatty_acids/synthesis_notes.md` | Created |

---

*Generated by supplement-research-pipeline Mode 2 | 2026-03-04*
